ALXN1210

FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria
GoinPharma
Fri, 12/28/18 - 01:00 pm
Alexion
FDA
ALXN1210
Ultomiris
PNH
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
Mon, 08/20/18 - 09:59 am
Alexion Pharmaceuticals
paroxysmal nocturnal hemoglobinuria
ALXN1210
How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass
Biopharma Dive
Tue, 06/19/18 - 09:40 pm
Alexion
Soliris
fast pass
FDA
priority review
ALXN1210
Alexion's follow-on stacks up to Soliris
Biopharma Dive
Fri, 03/16/18 - 11:19 am
Alexion
Soliris
ALXN1210
paroxysmal nocturnal hemoglobinuria
PNH